Adaptimmune Therapeutics PLC (ADAP)
0.9772
+0.04
(+4.29%)
USD |
NASDAQ |
Sep 27, 16:00
0.9751
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Research and Development Expense (Annual): 126.51M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 126.51M |
| December 31, 2022 | 127.73M |
| December 31, 2021 | 111.09M |
| December 31, 2020 | 91.57M |
| December 31, 2019 | 97.50M |
| December 31, 2018 | 98.27M |
| Date | Value |
|---|---|
| December 31, 2017 | 87.39M |
| December 31, 2016 | 63.79M |
| December 31, 2015 | 25.47M |
| June 30, 2015 | 24.14M |
| June 30, 2014 | 9.575M |
| June 30, 2013 | 8.150M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
91.57M
Minimum
2020
127.73M
Maximum
2022
110.88M
Average
111.09M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 17.22M |
| NuCana PLC | 31.19M |
| Autolus Therapeutics PLC | 130.48M |
| Mereo BioPharma Group PLC | 17.42M |